| December 13, 2012 | ISSUE NUMBER 280 VOL 8 |
Regulatory
FDA's Robert Temple 'Horrified' by Caronia Decision
If people can promote drugs for uses that lack supporting evidence, it would turn back the clock to the pre-1962 world of medicine where there wasn't any research or data on what medicines worked and what was harmful, says Robert Temple, deputy director for clinical science at FDA's Center for Drug Evaluation and Research (CDER) ...Read more
Global Launch in a Post-Blockbuster Era
What Life Science Companies Need to Know
Read insights, strategies and best practices from Advanstar's award-winning Pharmaceutical Executive magazine and IMS Health designed especially for industry executives, brand teams, and product managers to help them successfully launch their brands in a new and highly competitive global post-blockbuster era.  Click Here |
Event
New York Pharma Forum: Together We Stand
Participants in the 23rd Annual NYPF General Assembly last Friday outlined the many challenges facing industry, and the importance of collaboration as a way to move forward ...Read More
Payer/Pharma Collaboration: A "Real World" Research Strategy for Aligning R&D to Evidence-based Healthcare
Live Webcast: Thursday, December 13, 2012 at 2:00pm EST
Register Free at  http://www.pharmexec.com/aligning |
OTC Drugs
New Pseudoephedrine Drug Could Hop Back Over the Counter
On Wednesday Acura Pharmaceuticals launched its new pseudoephedrine-based product Nexafed, an over-the-counter product aimed at deterring abuse of the illicit drug methamphetamine. Pseudoephedrine has been subject to a federal statute which keeps medicines with the ingredient behind the counter of all pharmacies in the US, and limits the sale to consumers to less than 9 grams total of the drug per month
...Read more
Global
Read the December Pharm Exec Global Digest
Out today! In this month's issue: a new age of pharma procurement; trouble for Alzheimer's drugs in Europe; and latest developments in the Greek pharma/healthcare crisis
...Read more |
|
|
 // Eli Lilly appointed Dr Jean-Michel Cosséry as its new UK Managing Director and Vice President for its Northern Europe hub. // Indian generics company Dr Reddy’s Laboratories appointed Umang Vohra as the new head of its North American business. // Valeant (Montreal, Canada) has senior changes to its management team in the US following the acquisition of dermatology company Medicis. Ryan Weldon will be promoted to Executive VP/Company Group Chair leading US dermatology operations. Jason Hanson will be relocated from Medicis’ base in Arizona to join Valeant’s operations in New Jersey, where he becomes Executive VP/Company Group Chairman. Also, Medicis’ Executive VP, Sales and Marketing, Vince Ippolito becomes Senior VP, General Manager of Valeant’s aesthetics business, and Medicis Senior VP, Marketing (dermatology and aesthetics products), Justin Smith, will now serve as Senior VP, General Manager US Rx dermatology. |
|
|
|
|
|
 |
|
|
|
 |
|
 |
|
 |
Compared with last year, have you attended more or fewer industry events?
|
|
|
|
